<div id="readability-page-1"><div><p>Changchun BCHT Biotechnology Co. reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 474.44 million compared to CNY 1,026.01 million a year ago.</p><p>Net loss was CNY 158.25 million compared to net income of CNY 244.37 million a year ago. Basic loss per share from continuing operations was CNY 0.38 compared to basic earnings per share from continuing operations of CNY 0.59 a year ago. Diluted loss per share from continuing operations was CNY 0.38 compared to diluted earnings per share from continuing operations of CNY 0.59 a year ago.</p></div></div>

百克生物

<p>长春百克生物科技有限公司报告截至 2025 年 9 月 30 日的九个月内盈利大幅下降。销售额从去年同期的 10.26 亿元降至 4.7444 亿元。公司面临 1.5825 亿元的净亏损，而去年同期则实现了 2.4437 亿元的净利润。持续经营业务的基本和摊薄每股亏损均为 0.38 元，较去年同期每股盈利 0.59 元下降</p>

长春百克生物技术有限公司报告截至2025年9月30日的九个月财务业绩